Global Overactive Bladder Treatment Market – Industry Analysis and Forecast (2017-2024) _ by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation and Intravesical Instillation), by Disease Type (Idiopathic Overactive Bladder and Neurogenic Overactive Bladder), and by Geography

Global Overactive Bladder Treatment Market – Industry Analysis and Forecast (2017-2024) _ by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation and Intravesical Instillation), by Disease Type (Idiopathic Overactive Bladder and Neurogenic Overactive Bladder), and by Geography

Market Scenario

Global Overactive Bladder Treatment Market is expected to reach USD 4.44 Billion by 2024 from USD 3.52 Billion in 2016 at CAGR of 2.93% (Detailed analysis of the market CAGR is provided in the report). Global Overactive Bladder Treatment Market Overactive Bladder Treatment is basically a urinary incontinence, characterized by high urine frequency or nocturia, which includes urgency, high urinary frequency and urge incontinence. Overactive Bladder Treatment drugs are antagonizing cholinergic receptors that provide the relief from the frequent urination. Global Overactive Bladder Treatment Market is segmented by pharmacotherapy, disease type, and geography. Pharmacotherapy segment is sub segmented as anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. Disease type segment is bifurcated as idiopathic overactive bladder and neurogenic overactive bladder. Idiopathic overactive bladder segment is expected to dominate the market growth during the forecast period, owing to the increasing prevalence of bladder muscle weakness post pregnancy and menopause. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The rising prevalence of bladder overactivity and increasing geriatric population companies are trending the overall Global Overactive Bladder Treatment Market. However, undesired systemic effects caused by anticholinergic will restrain the market growth. North America is expected to dominate the Overactive Bladder Treatment Market in forecast period followed by Europe and APAC. Technologically advanced research platforms existence and developed healthcare industry with favorable reimbursement of overactive bladder treatment and increasing prevalence of the disease in this region will fuel the Overactive Bladder Treatment Market in North America region. Key Highlights: • Assessment of market definition along with the identification of key players and an analysis of their strategies to determine the competitive outlook of the market, opportunities, drivers, restraints, and challenges for this market during the forecast period • Complete quantitative analysis of the industry from 2016 to 2024 to enable the stakeholders to capitalize on the prevailing market opportunities • In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain • Global Overactive Bladder Treatment Market analysis and comprehensive segmentation with respect to the pharmacotherapy, disease type,, and geography to assist in strategic business planning • Global Overactive Bladder Treatment Market analysis and forecast for five major geographies North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions Research Methodology: Research methodology used in this report contains various secondary sources including Bloomberg, Hoovers, and Factiva. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Overactive Bladder Treatment Market globally. Key Players in the Global Overactive Bladder Treatment Market Are: • Apotex Inc. • Macleods Pharmaceuticals Ltd. • Medtronic PLC • Cogentix Medical, Inc. • Intas Pharmaceuticals Ltd. • Johnson & Johnson • Aurobindo Pharma Limited • Sanofi • Hisamitsu Pharmaceutical Co., Inc. • Endo International PLC • Mylan N.V. • Allergan, PLC. • Teva Pharmaceutical Industries Limited • Pfizer, Inc. • Astellas Pharma Inc. Key Target Audience: • Research and Consulting Firms as well as Venture capitalists, private equity firms, and startup companies • Drug manufacturers, vendors, and distributors • Contract manufacturing organizations (CMOs) • contract research organizations (CROs) • Academic and government research institutes • Government Bodies Scope of the Report: Research report categorizes the Global Overactive Bladder Treatment Market based on pharmacotherapy, disease type, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Overactive Bladder Treatment Market with key developments in companies and market trends. Global Overactive Bladder Treatment Market, By Pharmacotherapy: • Anticholinergics • Solifenacin • Oxybutynin • Fesoterodine • Darifenacin • Tolterodine • Trospium • Other Anticholinergics • Mirabegron • Botox • Neurostimulation • Intravesical Instillation Global Overactive Bladder Treatment Market, By Disease Type: • Idiopathic Overactive Bladder • Neurogenic Overactive Bladder Global Overactive Bladder Treatment Market, By Geography: • North America • Europe • Asia Pacific • Middle East & Africa • Latin America Available Customization: Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client.   Global Plasma Fractionation Market : Global Industry Analysis and Forecast 2024

Table of Contents

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY (2017-2024) 5.1. Introduction 5.2. Anticholinergics 5.2.1. Anticholinergics Market Overview 5.2.2. Anticholinergics Market Size & Forecast 5.2.2.1. Solifenacin 5.2.2.2. Oxybutynin 5.2.2.3. Fesoterodine 5.2.2.4. Darifenacin 5.2.2.5. Tolterodine 5.2.2.6. Trospium 5.2.2.7. Other Anticholinergics 5.3. Mirabegron 5.3.1. Mirabegron Market Overview 5.3.2. Mirabegron Market Size & Forecast 5.4. Botox 5.4.1. Botox Market Overview 5.4.2. Botox Market Size & Forecast 5.5. Neurostimulation 5.5.1. Neurostimulation Market Overview 5.5.2. Neurostimulation Market Size & Forecast 5.6. Intravesical Instillation 5.6.1. Intravesical Instillation Market Overview 5.6.2. Intravesical Instillation Market Size & Forecast 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE(2017-2024) 6.1. Introduction 6.2. Idiopathic Overactive Bladder 6.2.1. Idiopathic Overactive Bladder Market Overview 6.2.2. Idiopathic Overactive Bladder Market Size & Forecast 6.3. Neurogenic Overactive Bladder 6.3.1. Neurogenic Overactive Bladder Market Overview 6.3.2. Neurogenic Overactive Bladder Market Size & Forecast 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY GEOGRAPHY (2017-2024) 7.1. North America Overactive Bladder Treatment Market 7.1.1. North America Overactive Bladder Treatment Market, By Pharmacotherapy 7.1.2. North America Overactive Bladder Treatment Market, By Disease Type 7.1.3. North America Overactive Bladder Treatment Market, by Region 7.1.3.1. U.S. Overactive Bladder Treatment Market 7.1.3.2. Canada Overactive Bladder Treatment Market 7.1.3.3. Mexico Overactive Bladder Treatment Market 7.2. Europe Overactive Bladder Treatment Market 7.2.1. Europe Overactive Bladder Treatment Market, By Pharmacotherapy 7.2.2. Europe Overactive Bladder Treatment Market, By Disease Type 7.2.3. Europe Global Overactive Bladder Treatment Market, by Region 7.2.3.1. France Overactive Bladder Treatment Market 7.2.3.2. Germany Overactive Bladder Treatment Market 7.2.3.3. U.K. Overactive Bladder Treatment Market 7.2.3.4. Italy Overactive Bladder Treatment Market 7.2.3.5. Spain Overactive Bladder Treatment Market 7.2.3.6. Rest of Europe Overactive Bladder Treatment Market 7.3. Asia Pacific Overactive Bladder Treatment Market 7.3.1. Asia-Pacific Overactive Bladder Treatment Market, By Pharmacotherapy 7.3.2. Asia-Pacific Overactive Bladder Treatment Market, By Disease Type 7.3.3. Asia-Pacific Overactive Bladder Treatment Market, by Region 7.3.3.1. China Overactive Bladder Treatment Market 7.3.3.2. Japan Overactive Bladder Treatment Market 7.3.3.3. India Overactive Bladder Treatment Market 7.3.3.4. South Korea Overactive Bladder Treatment Market 7.3.3.5. Rest of Asia Pacific Overactive Bladder Treatment Market 7.4. Middle East & Africa Overactive Bladder Treatment Market 7.4.1. Middle East & Africa Overactive Bladder Treatment Market, By Pharmacotherapy 7.4.2. Middle East & Africa Overactive Bladder Treatment Market, By Disease Type 7.4.3. Middle East & Africa Overactive Bladder Treatment Market, by Region 7.4.3.1. South Africa Overactive Bladder Treatment Market 7.4.3.2. Rest of Middle East and Africa Overactive Bladder Treatment Market 7.5. Latin America Overactive Bladder Treatment Market 7.5.1. Latin America Overactive Bladder Treatment Market, By Pharmacotherapy 7.5.2. Latin America Overactive Bladder Treatment Market, By Disease Type 7.5.3. Latin America Overactive Bladder Treatment Market, by Region 7.5.3.1. Brazil Overactive Bladder Treatment Market 7.5.3.2. Rest of Latin America Overactive Bladder Treatment Market 8. MARKET COMPETITION ANALYSIS 8.1 Market Share/Positioning Analysis 8.2 Key Innovators 8.3 Company Profiles 8.3.1 Apotex Inc. 8.3.1.1 Overview 8.3.1.2 Products/ End-User 8.3.1.3 Strategy 8.3.1.4 Key Developments 8.3.2 Macleods Pharmaceuticals Ltd. 8.3.2.1 Overview 8.3.2.2 Products/ End-User 8.3.2.3 Strategy 8.3.2.4 Key Developments 8.3.3 Medtronic PLC 8.3.3.1 Overview 8.3.3.2 Products/ End-User 8.3.3.3 Strategy 8.3.3.4 Key Developments 8.3.4 Cogentix Medical, Inc. 8.3.4.1 Overview 8.3.4.2 Products/ End-User 8.3.4.3 Strategy 8.3.4.4 Key Developments 8.3.5 Intas Pharmaceuticals Ltd. 8.3.5.1 Overview 8.3.5.2 Products/ End-User 8.3.5.3 Strategy 8.3.5.4 Key Developments 8.3.6 Johnson & Johnson 8.3.6.1 Overview 8.3.6.2 Products/ End-User 8.3.6.3 Strategy 8.3.6.4 Key Developments 8.3.7 Aurobindo Pharma Limited 8.3.7.1 Overview 8.3.7.2 Products/ End-User 8.3.7.3 Strategy 8.3.7.4 Key Development 8.3.8 Sanofi 8.3.8.1 Overview 8.3.8.2 Products/ End-User 8.3.8.3 Strategy 8.3.8.4 Key Development 8.3.9 Hisamitsu Pharmaceutical Co., Inc. 8.3.9.1 Overview 8.3.9.2 Products/ End-User 8.3.9.3 Strategy 8.3.9.4 Key Development 8.3.10 Endo International PLC 8.3.10.1 Overview 8.3.10.2 Products/ End-User 8.3.10.3 Strategy 8.3.10.4 Key Development 8.3.11 Mylan N.V. 8.3.11.1 Overview 8.3.11.2 Products/ End-User 8.3.11.3 Strategy 8.3.11.4 Key Development 8.3.12 Allergan, PLC. 8.3.12.1 Overview 8.3.12.2 Products/ End-User 8.3.12.3 Strategy 8.3.12.4 Key Development 8.3.13 Teva Pharmaceutical Industries Limited 8.3.13.1 Overview 8.3.13.2 Products/ End-User 8.3.13.3 Strategy 8.3.13.4 Key Development 8.3.14 Pfizer, Inc. 8.3.14.1 Overview 8.3.14.2 Products/ End-User 8.3.14.3 Strategy 8.3.14.4 Key Development 8.3.15 Astellas Pharma Inc. 8.3.15.1 Overview 8.3.15.2 Products/ End-User 8.3.15.3 Strategy 8.3.15.4 Key Development

About This Report

Report ID6896
Published Date
Contact Us
Call Now